LiJe5cience!
l INDUSTRY
Fortnightly insight
Pharma
Systems 6i.ol.ogy~An Integrative
approach to drug discovery
Prabakar Sampath
. Tutorial on the applications
of Systems Biology for
Drug Discovery.
. Report on the current
scenario of Biotech
Parks in India for the
Entrepreneur and
Investor.
. Commentary on OMICS
for Drug Discovery.
. Tutorial on the
applications of Systems
Biology for Drug
Discovery.
. Update on Filtration
Techniques for
Industrial Bioprocess.
. Review on analysis of
Human Genome by
FISH technique for
Diagnostics & Medical
Technology.
Business & Market
\ ~..
,. . ; Bio. ProcessingBio
NEWS
for Life Science Professionals Volume 1 Issue 17 August 16-31. 2008 Rs.25/-
Biotech Biomedical Healthcare Diagnostics
The way biological systems were
perceived was changed almost five
decades ago by Watson and, Crick with their
identification of the DNA double helix...
The way biological systems were understanding has helped scientists
perceived was changed almost five to gain knowledge on the structure
decades ago by Watson and Crick and arrangement of biomolecules.
with their identification of the DNA However several properties of
double helix. Since then, enonnous living organisms arise at the system
advances have been made in level i.e. the interaction of
molecular biology in the molecules and this behaviour
understanding of biological cannot be explained merely by the
processes such as disease, constituents. Systems biology aims
evolution, heredity and at these systems level understanding
development on a molecular basis. of biological processes.
This molecular level of
Systems Biology...9
Blossoming
BiotechParksof India
AbhishekKumar Part _ I
Introduction characteristics, improved tools, like new
methods and techniques for upgrading
Biotechnology has created a massive
impact across the globe in every aspect of
life. In India, biotechnology is among the
animal' reproduction and quality, useful
microbes and food ingredients etc.
India- amongst the 12- biodiversity
fast growing knowledge based sectors. It
has been considered as a powerful enabling hotspots- is known for its abundant natural
technology that can revolutionize resources, quality manpower and
agriculture, healthcare, industrial infrastructure. Significant opportunities for
processing and environmental
sustainability. The industry moving ahead
the growth of biotechnology exist in India,
particularly in the agriculture and
healthcare sectors due to the large existing
with an annual average growth rate of 30-
35%. In the fiscal year 2007-08. the Indian
biotech industry' has posted revenues
and growing markets for food products and
phannaceuticals. Food production can be
increased substantially only by enhancing
Rs.IO,273 crore (US$ 2.56 bn) of which
2/3rd was contributed through exports i.e. productivity and reducing crop losses as
Rs. 5733.7 crores. Investments has touched almost all available land is already under
Rs. 2, 750 crore or up 21%. Biotechnology
is globally recognized as a rapidly
cultivation.
requirements
Moreover, health care
can be met only by the
production and use of cheaper drugs, both
emerging and far-reaching technology,
aptly described as the "technology of hope" preventive and curative.
for its promising role in food, health and
environmental sustainability. The
However, in the current scenario, the
developed countries are moving ahead
biotechnology-derived products range Report on the
much faster than the developing countries,
from bio-pharmaceuticals, diagnostics to current scenario of
due to their superior technological
transgenic food and field crops that have Biotech Parks in India
advancements, highly qualified scientists
aggressively introduced themselves in the for the Entrepreneur
and availability of financial and other
huge global market segment. The industry and Investor.
is striving to compete with desired quality Blossoming...2
Drug discovery Clinical Research
... Informatics I Omics DiagnosticsI Meditech
02 August 16 31,2008-

Publisher &<Manaj:inl: Editor

KR.I'iUai
krpiUai@,..manthi.m
BusinessMarket 01
Assistant Editor
Dr. ~I. Ita,;.. Ph.D.
mnn;@ad,'ancr:dbiorcch.in BlossomingBiotechParksof India - Report 04
Editorial A..istarn
~I. Gurulak,hnu
Graphic Design NewParadigmfor Drug DiscoveryResearch
K.~,Ia.L..,.:ac]j1
ProduCtion Medicines-Commentary
The'OMICS'RevolutionandPersonalised
.\bu Bucker
..
Office Addr"C'1I5 Drugdiscovery 01
Samamro Publica com rP, Ltd.
p.o. Box.:-;o.331-. Systems Biology: An Integrative approach to
drug discovery -Tutorial
1-('. J..:a'khn ("/.10",", ,",uncamhakkam.
Chc-nnai-(,/j, ":'4 India.
Ph, 91-44-2&1" 5693 94 / 2~1- 2M3
Editorial Diagnostics/Meditech 05
Email :emtor@,J.in.in
Subocription Analysis of Human Genome by
,ubl'cripoon(S:s.amanthi.in
Fluorescent insitu Hybridization(FISH)-Review
Sub..cription Rate
-
India J:-';R(,(NI/. Bio Processing 07
Advenisemeot
advm@!liamanthj.in
PubI , Dr 1(,R, 11I'11I8o
oro Mh8I' 01 Sem.rrtrto
FiltrationTechniques -Update
PwIIc8toOl'l8 P.,ot, Ltd. 81 1'0. IlCAtkQ"Colony.
~, o-w.. . 600 03" 8nd
P"I"teCIOJ' S
No,1/1'e.
Neg8f
MeOr88h8 ~
BwYt, 81 JoOo

Vorvgefftb8_"8'"
~.
$"1080Io~
C ,.".~...8OOOI2
BioInformatics
I Omics 08
EcMo< K.R p ~ Iv ~ 01
\,10\'" ~8 Act

Multiplexingfor RNAAnalysis
SAMANTHI PUBL.ICATIONS
ClinicalResearch 11
~oo..""'O'W<e-..ytCt'08
QDP8P1t ~...tt'Ie
..., "-.cy, ""'01'__ to...,.
~PII"D088_The~~"
~for8")'08"\I9IIO"~''''t''-
".._~dtl'oe~oO"
CareerOrientedProgramon ClinicalData Management
The__.~by"'~_~
----- , 00roo! ,. ~ tothe

Life ScienceEvents 12 NewLaunches 10

C ~"-ltl..
Published on 16 August 2008

Business & Market Report

Blossomjng...

resources. For developing players
like India. biotechnology stands as
is a powerful tool that can
r e ,. 0 I uti 0 n i z e a g r i cui t u r e.
health care. industrial processing
and en,'ironmental sustainability.
The Indian Biotechnology sector is
gaining global visIbility and is
anracting major investment
opportunities from abroad. India is
amongst the leading fi,'e biotech
leaders in the Asia Pacific regions.
others being Singapore. Taiwan,
Japan and Korea. with Mainland
China catching up quickly. India is
cUITentlyranked 3rd in the region
based on the number of biotech
companies (9(,I. trailing hchind are
Australia (228) and China.
including Hong Kong (136).
Looking back. after 1950s
accomplishments such as green
revolution (agriculture). white
revolution (milk) and se"eral other
e"ents gaw a strong wi11-powerand
motivation to build a strong base for
biotechnology in India.
The Indian Biotechnology industry
holding a global market share of
around 2%, is on its way of
becoming a USS 13-16 billion
(2015) industry where it has proved
its potential through its past uprising
trend. showing revenues of USS
2.56 billion, USS 2.08 billion. USS
1.5 billion and USSI billion during
2008, 2007, 2006 and 2005
respectively. The industry has a
huge biotech-market comprising of
sectors like agriculture. healthcare
(biophanna, therapeutics etc). bio-
services and bio-instrumentation
sectors has posted a growth of
30.98%. As a developing nation,
India offers a high potential in the
life science research due to its rich
biodiversity. abundant natural
resources. technical expenise. cost
etTective manpower base. world
class scientific infrastructure
coupled with fast developing
industrial infrastructure. There are
around hundred biological research
laboratories employing highly
qualified scientific and technical
manpower. more than 300 college
level educational and training
institutes across the country
otTering degrees and diplomas in
biotechnology, bio-infonnatics and
the biological sciences, producing
ncarly 5.00.000 students annually.
In India more than 100 medical
colleges are producing approx.
17.000 medical practitioners per
year. About 3,00,000 postgraduates
and 1500 Ph Os qualify in
biosciences and engineering each
year. These resources need to be
etTectively marshaled, championed
and synergized to create a
productive enterprise. [2]
India has laid great stress on
biotechnology. Recognizing the
potential of the industry, the
Government ofIndia had also taken
many initiations to boost the
industry. At the national level. the
Department of Biotechnology,
established in 1986 under the
Ministry of Science and
Technology, Government of India.
is undertaking the task related to,
commercialization of biotech
products and technologies,
biosafety regulations etc. The
department supports a number of
autonomous laboratories like the
National Institute of Immunology,
New Delhi; National Centre for Cell
Science. Pune; Centre for DNA
Fingerprinting &Diagnostics
(CDFD), Hyderabad; Institute of
Bioresource & Sustainable
Development (lBSD). Imphal.
Manipur: Institute of Sciences.
Bhuvaneswar; National Centre for
Plnat Genome Research (NBPGR), ]
New Delhi; National Bioresource
Development Board, National
Brain Research Institute, etc.
Research and development in the
above laboratories ranges from
microbiology, treatments for bum,
heart, and cornea transplant;
germplasm banks for plants,
animals, algae, and microbes; viral
vaccine; animal embryo
technology; animal and human
fertility control; communicable and
genetic disease prevention: and
biofertilizer, biocontrol, and
biomass agents. The department
also controls two state-owned
enterprises involved in vaccine
production. the Bharat
Immunologicals and Biologicals
Corporation and the Indian
Vaccines Corporation, both in New
Delhi. CSIR oversees numerous sub
Blossoming...6
 06 . AUVlI:.1
. Review
Diagnostics / Meditech
---
Analysis.....
PND Amniocytes Metaphase
Prenatal Genetic Diagnosis
alpha satellite probes can be used in FISH
studies to document chromosome gain or
loss in cells that are not dividing.
Interphase c~10genetics using FISH is a
rapidly growing field. One can enumerate
the number oftluorescent signals present in
interphase nuclei. for instance using an
alpha satellite probe for the centromere of
chromosome 18. or a unique cosmid
sequence fora locus on chromosome21.
3. Microdeletion syndromes
Syndromes such as Prader-Willi.
Angelman. Di-George or Smith-Magenis
are characterized as chromosome deletion
s~l1dromesby high-rcsolution cytogenetic
analysis of prometaphase chromosomes.
The term micwdeletion syndromes are
commonl~ applied to these. These
deletions being small are sometimes
Bloss0ming...
national biotechnology institUtions.
These include the Central Drug
Research Institute (Lucknow);
Centre for C~lIular and \lolecular
Biology (Hyderabad); the Indian
Institute of Chemical Biology
(Ca!cuna); and the Institute of
\1 i c rob i a I T e c h n 0 log y
(Chandigarh) among others.
\foreover. we can see that biotech
development is mainly centered in
the southern states of India i.e.
Andhra Pradesh. Karnataka. Tamil
J\"adu and Kerala where Genome
Valley and Silicon Valley are
situated and arc on thc expansion
phase. The outcome of biotech
developments can be seen with
some exciting examples like
introduction of hepatitis B vaccine.
which was first manufactured by
Shantha Biotechnics in Andhra
Pradesh. \laharashtra is the second
largest biotech centrc. and its base
continues to expand in places like
I (I J I, 10011
-- --- .-
high-risk patient samples with
chromosomal abnonnality ifany.
Conclusion
The dcvelopment of DNA in situ
hybridiz.3tion (DISH) and RNA in situ
Hybridization. (RISH) probes has
advanced in various directions. Probe
DiGeorge Syndrome ishdel(22)(q11.2) labeling methods have been either by direct
tagging of the fluorochrome to the
undetectable as in the case of Williams's
nucleotides or by indirect biotin or
syndrome. Cosmid probes have been digoxigenin labelling. The latter has
developed that recognize unique DNA potential role in detection of very small
sequences within the critical region of sequences. Fluorochromes, methodology.
chromosomal deletion for several of the
filters. filter wheels and image analyzers
micro-deletion syndromes. Thc have proved Ihat molecular cytogenetics
commercial availability of these probes has has potential application in several areas
made lahoratory diagnosis of these i.e.. evolution. ageing. cancer. genctic
syndn:uncs Inur\.~ a(.,",:urah:.
syndromcs and di:lgnostic assays - comct.
micronuclci and chromosomal abnonnality
4. FISH in pre-implantation
studies. Hybridization combined with
diagnosis (PGD) inununo-fluorcscenl'c h:ls paved way for
new research and clinical avenues in gene-
mapping. chromosomal and gene
abnormalities. gene expression. genome
organization. as well as identification of
infectious diseases. The use of non-isotopic
probes has also led to the development of
other rapid assays like Real Time PCR.
automated sequencing, Image cytometry
and micro array technology. Automation
of chromosome analysis has progressed to a
new era of the colorful world of DNA and
Pre-implantation genetics is the latest
RNA. (To becontd. next issue).
advancement in chromosome painting - to
identify chromosomal aberrations prior to
(Authors - Solomon ED. Paul.
embryo implantation in couples that have
Vijayalakshmi J.. Koshy T.. Karur H..
opted for IVE When the growing embryo is
at the 4-Rth cell stage teeming with Vcnkc(swaran N.. & Venkatachalam P..
totipotent blastomcrcs. blastomeres are Dep!.. Of Human Genctics
removed using a mieromanuplator. The Sri Ramachandra University. Porur.
hybridisation of a suitable DNA probe to Chennai - 116.
these blastomeres will help in ruling out Email: wise_soly@yahoo.com
Ahmedabad. Chandigarh. Delhi & chalk out the path of progress in issues of biotechnology. fostering
:>iCR. and in some cities of agricultural biotechnology. food the micro. small and medium
Himachal Pradesh and biotechnology. industrial enterprises in India through various
t.:l1arakhand.[3] biotechnology. therapeutic and government initiatives. Biotech
medical biotechnology. Consortium India Limited. a
The National Biotechnology regenerative and genomic company promoted by Depanment
Development Strategy. the policy medicine. diagnostic of Biotechnology is working for the
framework developcd by biotechnology. bioengineering. commercialization of
Department of Biotechnology. nanobiotechnology. bio-informatics biotechnology. Since the last 15
Govt. oflndia. is the result of a great and IT cnabled biotechnology. years, the company is actively
deal of brain storming and clinical biotechnology. involved in projects like
consultation with the stakeholders
manufacturing & bio-processing. development of detailed business
(scientists. educationists. policy research services. bio-resources. plan for the biotech parks,
regulators. representatives of environment and intellectual assessment of the viable
society etc.). It had focused on propeny & patent law. National technologies for
critical issues like human resource
Biotechnology Development commercialization, creating
dcvelopment. as an intcrfacc Strategy has strengthened the Indian awareness among the people about
hetween academia and industry. academia and industry in many biolechnology and manpower
infrastructurc dcvclopmcnt. lab ways such as. linking thc training and placement in
development - maintenance and government with academial biotechnology. [4]. (To be contd.
manufacturing. promotion of industry and supporting the next issue).
industry and trade. development of industries to take steps for
biotechnology parks and commercialization of the outcome (Author - Abhishek Kumar
incubators. rcgulatory mcchanisms. Biotcch Consonium of India.
of research thus cre:uing an
building public education and Email:
awareness among the people about
awareness. This policy also aims to the advancements- benefits and kumarabhishek _13@yahoo.co.in)
 Business It Market Report

Blossoming
Abhishek
BiotechParksof India- Part-II
Kumar

Biotechnology Park is an inftastructure
based on the concept of public-private-
partnership. The park stands ~ a single
common platform for the eRtreprenelH'Sto
commercialize their productsl technology
thus scaling it from lab to industry level.
The park extends provides support in the
development and commercialization of the
viable biotechnologies. These parks are a
boon for the small and medium scale
enterprises (SMEs) and existing players in
life science industry. Some of the existing
biotechnology parks include:
Biotechnology Park (Lucknow), TlCEL
(Chennai), ShapooJjii Pallonji Biotech
Park (Hyderabad), etc. many new parks are
also proposed to be setup in the coming
years in Chhattisgarh, Madhya Pradesh,
Kerala, Haryana and Punjab. The Genome
Valley is India's first state-of-the-art
biotech cluster providing world-class
infrastructure to over 100" biotech
companies. Spread over an area of 600 sq.
km, it is a natural cluster for biotech
research, training, collaboration and
manufacturing activities with some of
Jndia's leading biotech institutions and
companies located here. The Genome
Valley encompasses established biotech
parks ShapooJji Pallonji Biotech Park and
ICICI Knowledge Park.
The biotechnology parks are established to
provide a common platform for research
and commercialization of biotechnology to
the researchers and entrepreneurs, which
aim at:
I. Providing state-of-the-art- inftastructure
to the industry for R&D and production of
biotech products. This would contain
facilities in the incubator which include
physical facilities like office space, dry and
wet laboratories, specialized equipment
and instrumentation facilities, pilot plant
and scale up units and good communication
netWork. 2. Facilitating the technology
transfers. 3. Strong linkage and support
from the existing inftastructure in the state.
4. Goveinment's support for the Small
Medium Enterprises (SMEs) in form of
fund assistance. S.Single window facility
to the tenants of the park when the stage of
trials and regulatory checks come.
Building a Biotech'notogy Park'
Biotechnology Park is a large scale project
that calls for an investment worth hundreds
of crores of rupees. The park is managed in
three different ways:
.. Funded and run by government body
Funded by government and managed by
the private partner .Completely established
and managed by a private partner
In a model where park is setup is set up by
the government and managed by the private
partner, the major factor of concern i.e. land
requirement, is either met ny the
government (as equityl grant) or from the
potential private partner, who is
responsible for the building the park. Some
of the parks are built in around 20-40 acres
whereas some are allotted approx. 600-700
acres ofIand. The capital investment for the
park is in the range of Rs.200-400 crores,
depending on the equipment and facilities.
A Biotechnology Park comprises of
facilities like Technology Incubation
Centre housing the modular labs,
specialized facilities, central
instrumentation facility and the pilot plant
facility; Common Facilities (Common
Effluent Treatment Plant. Cold storage and
warehouses); Business Support Facility
comprises of administrative office,
cafeteria, commercial shops, dispensary,
meeting rooms and parking. These parks
are also equipped with uninterrupted water
and power supply. To promote the
development of biotech clusters in the
country, central as well as the state
governments offer many special incentive
packages in form of relaxation in Floor
Area Ratio (FAR), exemption in customs
duty, income tax benefit under (801A) to
developers for any block of 10 years in IS
years, duty free import/domestic
procurement of goods for development etc.
Technology Incubation Centre (TIC) is
known as the heart of the Biotech Park. This
centre is equipped with ready to use
modular labs. The facilities in TIC can be
beneficial for the tenants involved in
research and pilot scale manufacturing,
clients from academia and industry. It
encompasses the sector specific R&D
activities li"ke agriculture (herbal
extraction, biopesticidel biofertilizers,
transgenicl GMOs); healthcare (rDNA
therapeutics, vaccines, diagnostics, animal
healthcare, clinical trials); industrial and
environmental (enzymes, biodiesels etc.)
and even bioinformatics.
India is undergoing a biotech revolution,
where the existing as well as upcoming
biotech parks would stand.like a backbone
for the future biotech R&D and product
development. These biotechnology parks
are well established and are on the phase of
expansion. Each and every biotech park has
its significance according to the thrust areas
in the state. ~
Report on the
Some of the parks like TICEL Tidco - current scenario
Centre for Life Sciences Bio Park, Chennai, of Biotech Parks
in India
have unique facilities for marine research
for the
also. However, the industry is flourishing in
Entrepreneur
the northern region of India. Ststes like,
and Investor.
Haryana, Punjab, Himachal Pradesh,
Uttaranchal, Uttar Pradesh have taken
major step in this regards. Almost every
sector has come up with its State
Biotechnology Policy as a guidance map to
boostup biotechnology in respective
region. Lets see Uttar Pradesh- though,
U .P. was not of good interest for the private
players in biotechnology but now it has
came to be recognized as a priority sector
for R&D and manufacturing in north India.
In 2002, Lucknow was blessed with the title
of 'Biotechnology City' comprising of a
good number of scientific laboratories
working in various field of biotechnology,
pharma, medical research. However, Gov\.
of Uttar Pradesh took this initiative very
late but the establishment of Biotech Park J
has played a significant role in creating an
interest among the industries for their
expansion in Uttar Pradesh (V.P.). The park
was built in an area of 8 acres in
Blossoming...5

Business & Market 0 N evvs

WHO. Zydus sign pact to through the use of monoclonal The WHO will be providing public, including in particular its
develop drugs for rabies antibodies (MAbs), the next- monoclonal antibodies capable of availability to the public sector of
generation biologicals. neutralising rabies virus and genetic developing countries at a
Cadila Healthcare Ltd, sequences therenf, for evaluation at preferential price, the Ahmedabad-
(Zydus Cadila) has entered
into an agreement with
World Health
)( The agreement is a broad-based one,
which includes evaluation and
provides a possible stepping-stone
the Zydus Research Centre, the
research arm of the pharmaceutical
major here. The development and
based company said here on
Thesday.
for the development and commercialisation of the cocktail Source:www.ahmedabadcommunit
Organisation (WHO) to explore
commercialisation of ,the cocktail, will, among others, be designed to y.com!
collaboration in the development of
a cocktail for the treatment of rabies, to be used as an adjuvant therapy. achieve its wide availability to the

-
04 I UfeSciencesIndustryNews I September 01 15. 2008
 "Business & Market Report

Blossoming...

Table -1 Biotech Parks of India Biotechnology is a ray of hope for many of

S.No. Biotechnology Park Address the problems linked to man as well as
nature. It has the potential 10 develop more,
1. LucknowBiotechPark SectorG,Jankipuram,
KursiRoad,Lucknow.226021,
U.P.
www.biotechciMucknow.org Fax:91-522-4012081,
Tel.0522-2365050/4012091/2733174 provided it meets the indusny standards
2. ICICIKnowledgePark ICICIBankTowers,LevelIV:StreetNo.1, 11-1-256Begumpet. like quality products, advanced technology,
www.icicikp.rom Hyderabad- 500016 significant production etc. Biotech parks in
Tel:040-23480022/ 03;Fax:040-23480007 India have come as a boon and will boost
3. International ..
BiotechPark 304.EnterpriseCentre,VileParle(East).Mumbai40b099. biotechnology industry in India.
www.ibpI.net Tel:26172555/66; Fax: 56772575.
Consequently, India would also become an
4. ShapoorjiPallonjiBiotech No:A-2.1stFloor,Lane1,StreetNo.3,IndianAirlinesColony,
ParkPvt.Ltd. -
Begumpet,Secunderabad500003,A.P.
international loe<ltion for biotechnology
like Cornell University, University of
www.spbiotechpark.rom Tel:+91-40-27900893,27902009
5. nCEL Bio]Park Chennai-600 113
TararnaniRoad,Tararnani, Minnesota, Manchester Science Park Ltd,
www.ticelbiooark.com Tel:91-44-22542061/2062;Fax:91-44-22542055; Technology Park Malaysia etc. The
6. GoldenJubileeBiotechPark SiruseriVillage,InsideSIPCOT-ITPark,OldMahabalipuram biotech-revolution in India has resulted in
ForWomenSociety Road.NavalurPost,Kanchipuram District-803103 form of outsourcing, collaborations and
www.biotechpark.com Tel: 044-32900973/32906313
foreign direct investments (FDIs). Foreign
companies have shown their interest and
collaboration with Department of projects for the commerciali7.ation of many arc coming invesling in India. India is
Biotechnology (DBT) and the Council of biotechnologies. In this regard department amongst the top global players, and playing
Scientific & Industrial Research (CSIR), extends financial and advisory support in a major role in the biosciences research and
New Delhi. universities and industries. At form ora restricted amollnt of funds, up to development in world.
present many renowned companies like 70% of the total project cost, while the
Life Care Innovations. Delhi: Clint~eh balance amount of 30% is expected to be Acknowledgement
Research LLC, New Jerse.y;Biotechno]ogy met by the stake holders/promoters.
Consulting Research,Inc. are coming up in Besides these the state governments of .. I am grateful to Prof. P. K. Seth, CEO,
Biotechnology Park- Lucknow. Indian are also extend their help in the Biotech Park, Lucknow for his thoughtful
development and promotion of the guidance, encouragement, sagacious
Services from the Biotech Park Biotechnology Park through their Biotech advices, valuable suggestions in
Policy where attractive incentive and developing and disseminating this
Biotech parks in India are the outcome of information regarding the role of biotech
package are offered. to the prospective
DBT's National Biotechnology investors. parks in India."
D::n:!opment Strategy'. The Parks offers a
platform for the rising small players of Although, the Biotechno]ogy Parks are References
biotechnology to establish themselves. meant for pilot scale production of the
Small and Medium Enterprises (SMEs) and products developed in laboratories of I. Biotech sector revenues cross Rs 10,000
the prospective entrepreneurs are tenants but the academic institutions can cr, The Hindu-Business Line, July ]7,
encouraged to come forward with potential take the advantage of the facilities and 2007
and feasible technologies {ideas for setting services of the parks in the form of
up new ventures. Biotech Parks offer equipment, etc. III addition, Biotech Parks 2.lndia's Biotechnology Industry Is
facilities, services in form of modular lab, Blooming; Biotech India; Thursday,
can also offer short term trainings to the
equipment and consultancy for transfer and August 16,2007)
students and research scholars working in
commercialization of technology. There the area of biotechnology, as these kinds of 3.lndian biotechnologyrapidly evolving
are different funding schemes from services would act as the source of revenue
and industry led, Nature Biotechnology,
government for the technopreneurs and for the parks. Volume 22 supplement, December 2004,
SMEs like. New Millennium Indian
ppDC31 - DC36)
Technology Leadership Initiative Conclusion
. (NMITLI). Small Business Innovation
Research Initiative (SBIRI) which act as Country's biotechnology revolution is
4. Section I-III of National Biotechnology
Development Strategy, Department of
o
grant-in-aid and'or soft loans for moving ahead wth a great acceleration thus Biotechnology, Gov!. ofIndia, 2005.)
technology or product development to the changing the total scenario of science and
indusny. Department of Biotechnology,
Government of India has initiated several
-
technology is changing making R&D, a
(Author: Abishek Kumar, M.B.A.,
Biotechno]ogy Management)
commercially potential sector.
E-Mail: kumarabishek_13@yahoo.co.in

Business & Market 0 N e\NS

Mitosciences and Roche apply its MitoToxTM technology to effects, and the growing recognition solution for measuring every known
Pharma Collaboration provide in vitro data for a broad set of mitochondria as important sites xenobiotic mito-toxic mechanism,
ofmitocbondrial toxicity endpoints. of such effects, the MitoToxTM from direct effects on OXPHOS to
MitoSciences Inc. announced an technology is receiving a great deal alteration of mitochondrial
Using the MitoToxTM technology of attention and is being applied by biogenesis to induction of apoptosis
agreement with Roche Pharma to
drug companies can identify early in drug companies both large and and everything in between, so the
generate mitochondrial toxicity
the drug development process the small. The project with Roche is results from this study should
profiles for over 100 known kinase
specific sites and mechanisms of very exciting as it will be the first provide a very comprehensive data
inhibitors. Under the agreement
drug-induced mitochondrial such study looking at the specific set to inform future drug
''1Che will provide the compound
inhibition. Given the increased
"V plus previously-gathered mito-toxic effects of a large set of development
'Ul in vivo and in vitro emphasis by drug companies on well-characterized kinase
'.and MitoSciences will
earlier identification of toxic Source: www.businesswire.com
inhibitors. MitoToxTM provides a

OS I LifeSciences Industry News I September 01 - 1S. 2008